ChemoCentryx, Inc.; Proposal To Withdraw Approval of New Drug Application for TAVNEOS (Avacopan) Capsule, 10 Milligrams; Opportunity for a Hearing
🏛 Food and Drug Administration (FDA)FDA-2026-N-1321
Documents
4
Total comments
93
all analyzed
Comment status
Closed
Last activity
Jun 29, 2026
In this docket
Documents
Rules, notices, and supporting material — the primary rule pinned first.
📄 Primary document
OtherJun 24, 2026
OCC Separation of Functions ChemoCentryx -Amgen Tavneos (avacopan)No comment period
- Other· Jun 24, 2026No comment period
- Other· Jun 24, 2026No comment period
- Notice· Apr 30, 2026Closed on Jun 30, 2026💬 93